New award for metformin hydrochloride (HCL) 24HR sustained action (SA) tablets period is december 30, 2025 - december 29, 2026 with four one-year options.

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79726D0002
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 85% complete
IDV ceiling
$90,709,478.30
Award type
Single award
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 2 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

The National Acquisition Center awarded an indefinite-delivery contract to Avkare LLC on December 30, 2025, with a ceiling of $90,709,478.30 for Metformin Hydrochloride 24-hour sustained-release tablets. This is a single-award contract with no set-aside. The base period runs through December 29, 2026, with four one-year options available. Place of performance is Pulaski, Tennessee.

The originating solicitation sought unrestricted commercial-item procurement of Metformin HCL tablets in 500 mg and 750 mg sustained-release strengths to supply the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center through existing Pharmaceutical Prime Vendor Programs. The solicitation (36E79725R0051) posted June 23, 2025, with proposals due July 28, 2025. Offerors were required to provide products under unique NDC numbers with their own labeling and meet specific packaging specifications including safety-caps, bottles of minimum 120 cc volume with 5.75-inch circumference, and compatibility with 5.25" x 2" labels. Estimated annual requirements exceeded 1.1 million bottles across nine line items, with highest-volume demand in 500 mg tablets across multiple bottle-count configurations.

The contract falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing). The award incorporated Section 5 of Executive Order 14398, addressing discrimination concerns under FAR clause 52.222-90.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00002 · Modification incorporates section 5 of EO 14398, clause 52.222-90, addressing DEI discrimination $0
Add Subcontract Plan P00001 · Modification to avkare contract to incorporate 2026 subcontracting plan for metformin hydrochloride (HCL) 24HR sustained action (SA) tablets. $0
Original award $0

Quick answers

Who was awarded contract 36E79726D0002?

36E79726D0002 was awarded to Avkare LLC by National Acquisition Center (Headquarters) on December 30, 2025.

How much is contract 36E79726D0002 worth?

36E79726D0002's own ceiling is $90,709,478.

Who can order from contract 36E79726D0002?

36E79726D0002 is a single award indefinite delivery contract.

Was contract 36E79726D0002 competed?

The extent of competition for 36E79726D0002 was full and open competition. The government received 2 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV